Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Patel, Snehal T.
Languages: English
Types: Doctoral thesis
Subjects: RC0254
The aim of this study was to investigate the role of the adipokine visfatin as a possible\ud molecular mediator between obesity and prostate cancer.\ud Visfatin, an adipokine that is elevated in obesity and has many proposed roles and has\ud been linked to a variety of cancers. No data pertaining to the role of visfatin in prostate\ud cancer existed and this was an area that this study looked to address. It is suggested\ud that obesity is a significant risk factor for prostate cancer; in particular, aggressive\ud disease and adipokines have been investigated as a link for this hypothesis.\ud This study presents novel data demonstrating the expression of visfatin in the LNCaP\ud and PC3 cell lines as well as in benign and cancerous prostate tissue at both mRNA\ud and protein level. Furthermore visfatin is shown to have functional roles in autoregulation\ud and promoting increased cell proliferation in PC3 cells and also showed\ud further effects with respect to cell migration across a wound. These data gave promise\ud to develop the study further and evaluate potential mechanisms of action including\ud common second messenger systems such as MAPK and also other oncologically\ud multifunctional molecules in the forms of MMP-2/-9. We then demonstrated that visfatin\ud up-regulated MAPK phosphorylation and MMP mRNA/protein expression and more\ud importantly MMP-2/-9 zymographic activity. This provided possible mechanisms by\ud which visfatin may mediate a role for obesity driven aggressive prostate cancer.\ud The study then looked to evaluate NMN (the byproduct of visfatin catalysed\ud biosynthetic activity), as well as the visfatin inhibitor FK866 which is being evaluated as\ud chemotherapeutic agent. Unsurprisingly NMN and FK866 had opposing actions on\ud proliferation and FK866 was naturally proapoptotic. NMN was able to rescue the effect\ud of FK866 on PC3 cell apoptosis. Prior studies have shown that NMN did not affect\ud oncogenes however NMN was found to significantly reduce BAX mRNA expression in\ud PC3 cells.\ud The findings are consistent with other studies linking visfatin with cancer states. These\ud novel data indicate roles for visfatin in prostate cancer and possible mechanisms linking\ud obesity and prostate cancer.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [2] Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105-13.
    • [3] Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.
    • [4] Buschemeyer 3rd WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331-43.
    • [5] Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
    • [6] Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2002;34-41.
    • [7] Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, et al. Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. J Biomed Biotechnol 2008;2008:163902.
    • [8] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev 2001;1:34-45.
    • [9] Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-43.
    • [10] Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97.
    • [11] Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81.
    • [12] Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
    • [13] Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-8.
    • [14] Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999;463: 77-82.
    • [15] Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, et al. MMP2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007;27:1519-25.
    • [16] Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
    • [17] Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007;357:150-6.
    • [18] Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003;544:74-8.
    • [19] Mistry T, Digby JE, Chen J, Desai KM, Randeva HS. The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 2006;348:832-8.
    • [20] Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol 2007;52:46-53.
    • [21] Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int 2002;90: 162-73.
    • [22] Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006;208:401-7.
    • [23] Saarialho-Kere UK, Chang ES, Welgus HG, Parks WC. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 1992;90: 1952-7.
    • [24] Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 2008;8:10.
    • [25] Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7.
    • [26] Simon M. Bush supersizes effort to weaken the World Health Organization. Int J Health Serv 2005;35:405-7.
    • [27] von Hafe P, Pina F, Perez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 2004;12:1930-5.
    • [28] Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissuederived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009;81:370-80.
    • [29] Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of proteaseactivated receptors. Prostate 2004;60:168-74.
    • [30] Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007;80:201-10.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article